Clinically relevant pharmacokinetic drug interactions in the intensive care unit: An overview;Klinisch relevante pharmakokinetische Arzneimittelinteraktionen in der Intensivmedizin: Eine Übersicht

Medizinische Klinik - Intensivmedizin und Notfallmedizin

Volumn 107, Issue 2, 2012, Pages 128-140

  Kammerer W ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

CYP enzymes; Drug interactions; Intensive care unit; P glycoprotein; Pharmacokinetics

Indexed keywords

ARTICLE; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; INTENSIVE CARE UNIT; PHARMACODYNAMICS; BIOTRANSFORMATION; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG DETOXIFICATION; DRUG INTERACTION; DRUG POTENTIATION; ENZYME INDUCTION; FEMALE; INTENSIVE CARE; PHARMACOKINETICS; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW;

CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; HUMANS; INTENSIVE CARE; METABOLIC DETOXICATION, PHASE I; P-GLYCOPROTEIN; PHARMACOKINETICS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84864043255     PISSN: 21936218     EISSN: 21936226     Source Type: Journal    
DOI: 10.1007/s00063-012-0099-9     Document Type: Article

References (31)

1. Bates DW, Tony Yu D (2003) Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc) 39: 801-813.
2. Boucher BA, Wood GC, Swanson JM (2006) Pharmacokinetic changes in critical illness. Crit Care Clin 22: 255-271.
3. Carcillo JA, Doughty L, Kofos D et al (2003) Cytochrome P-450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 29: 980-984.
4. Chang KC, Bell TD, Lawer BA (1978) Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet I: 1132-1133.
5. Cheng JWM, Frishman WH, Aronow WS (2009) Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Ther 16: 155-163.
6. DrugReax Datenbank (CD-ROM), Micromedex Inc., 2011.
7. Eberl S, Renner B, Neubert A et al (2007) Role of P-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46: 1039-1049.
8. Elbarbry FA, Marfleet T, Shoker AS (2008) Drug-drug interactions with immunosuppressive agents: Review of the invitro functional assays and role of cytochrome P450 emzymes. Transplantation 85: 1222-1229.
9. Fachinformationen: http://www. fachinfo. de (Stand 31. 12. 2010).
10. Internet, Drug information for professionals: http://www. drugs. com.
11. Internet, DrugInfo: http://www. medscape. com.
12. Internet, medicine. iupui. edu/clinpharm/ddis/.
13. Internet, http://www. kardiolab. ch/CYP450_2JSI. html.
14. Internet, http://www. mediq. ch.
15. Internet, http://www. ncbi. nlm. nih. gov/pubmed/.
16. Kämmerer W, Mutschler E (1993) Arzneistoffwechselwirkungen in der Intensivmedizin. Rhein Main Druck, Mainz.
17. Kämmerer W (2005) Klinisch wichtige Interaktionen von Antimykotika. Arzneimitteltherapie 23: 72-79.
18. Kämmerer W (2011) Klinisch relevante Interaktionen mit Rifampicin: ein Update. Chemother J 20: 18-24.
19. Kitteringham NR, Pirmohamed M, Park BK et al (1998) The pharmacology of the cytochrome p450 enzyme system. Baillères. Baillieres Clin Anaesthesiol 12: 191-211.
20. Landrum Michalets E (1998) Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18: 84-112.
21. McKindley DS, Hanes SD, Boucher BA (1998) Hepatic drug metabolism in critical illness. Pharmacotherapy 18: 759-778.
22. Olkkola KT, Ahonen J (2001) Drug interactions. Curr Opin Anaesthesiol 14: 411-416.
23. Pai MP, Mammary KM, Rodvold KA (2006) Antibiotic drug interactions. Med Clin North Am 90: 1223-1255.
24. Papaopoulos J, Smithburger PL (2010) Common drug interactions leading to adverse drug events in the intensive care unit: Management and pharmacokinetic considerations. Crit Care Med 38(Suppl): S126-S135.
25. Papp-Jámbor C, Jaschinksi U, Forst H (2002) Cytochrom-P450-Enzyme und ihre Bedeutung für Medikamenteninteraktionen. Anaesthesist 51: 2-15.
26. Park GR (1996) Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 77: 32-49.
27. Rivkin A (2007) Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 64: 1840-1843.
28. Romac DR, Albertson TE (1999) Drug interactions in the intensive care unit. Clin Chest Med 20: 385-399.
29. Saad AH, DePestel D, Carver P (2006) Factors influencing the magnitude and clinical significance of drug interactions between azole fungals and select immunosuppressants. Pharmacotherapy 26: 1730-1744.
30. Smithburger PL, Kane-Gill SL, Benedict NJ et al (2009) Significance of drug-drug interactions in cardiac intensive care units. Crit Care Med 37: A460.
31. Zhou SF, Xue CC, Yu XQ et al (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29: 687-710.